The present, invention pertains to cyclic peptides, combinations of cyclic peptide having potent antibacterial effects, as well as pharmaceutical compositions for use as medicaments, in particular for treating bacterial infections. The backbone - cyclic peptides are made of an even number of 6-20 amino acid residues, wherein every second residue has a fully substituted beta-carbon atom (i.e. beta - trisubstituted amino acid, such as tert-Leucine and penicillamine). The peptides contain a cluster...

The invention provides an effective amount of a diketopiperazine having the following formula for use in the treatment of a T-cell mediated disease from an unwanted delayed-type hypersensitivity reaction: wherein: R 1 and R 2 , which may be the same or different, each is: (a) a side chain of an amino acid, wherein the amino acid is glycine, alanine, valine, norvaline, +--aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminobutyric acid, leucine, isoleucine, norleucine, serine, homoserine, t...

The invention provides an effective amount of a diketopiperazine having the following formula for use in the treatment of a T-cell mediated pulmonary disease or an autoimmune disease: wherein: R 1 and R 2 , which may be the same or different, each is: (a) a side chain of an amino acid, wherein the amino acid is glycine, alanine, valine, norvaline, +--aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminobutyric acid, leucine, isoleucine, norleucine, serine, homoserine, threonine, aspartic ac...

Articles of manufacturing, methods, devices and compositions for preventing or reducing tobacco-associated damage in a subject, and which utilize a metal ion chelating agent, a copper chelating agent, a penicillamine and/or a structural analog of penicillamine, with and without an additional antioxidant, are disclosed.

The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate gold compounds antimalarials cyclosporine A leflunomide azathioprine sulfasalazine d-penicillamine aurothioglucose auranofin or a TNF inhibitor.